Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 135

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 135
---
.15 million, or 4%, was driven by a decrease in losses attributable to the owners of the Company of £0.26 million, offset
by higher negative non-cash items.

Net cash outflow from operating activities before changes in working capital was £7.62 million in the year ended December 31, 2023, as opposed to £8.25 million during the same period in 2022.

| 69 |

This reduced cash outflow of £0.62 million was driven by lower losses attributable to the owners of the Company of £0.58 million and a lower tax credit of £0.43 million, offset by reduced share-based payment expenses of £0.10 million and an increase in net finance income of £0.08 million. Included in cash flows from operating activities in 2023 was £0.08 million in respect of the forgiveness of a loan to Adhera and in 2022 was £0.21 million in respect of impairment of a loan to Bioasis.

Cash Used in Operations.
Working capital increased in cash flow terms by £0.87 million for the first six months of 2024, compared to a decrease of £0.21
million for the same period in 2023. The increase in the six months ended June 30, 2024 primarily comprised an increase in trade
and other receivables of £1.30 million offset by a decrease in trade and other payables provisions of £0.43 million.

Working capital increased in cash flow terms by £0.05 million for the year ended December 31, 2023, compared to a decrease of £0.52 million for 2022. The increase in 2023 primarily comprised of an increase in trade and other payables of £0.21 million offset by the utilization of £0.21 million provision in respect of expected losses on a loan provided to Bioasis and a reduction in debtors of £0.37 million.

Taxes Paid. Taxes paid
in the six months ended June 30, 2023 and 2022 were £nil. Taxes paid in the years ended December 31, 2023 and 2022 were £nil.

Research and development tax credits of £0.84 million were received in 2023, as opposed to £0.68 million in 2022. This related to claims submitted in the prior financial year.

Investing Activities

There was no purchase of property,
plant and equipment in the